TECTONIC THERAPEUTIC, INC. (TECX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 72.19M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 13.02M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -94.92M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $72.19M | (m) | $13.02M | $-94.92M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $71.32M | (m) | $11.60M | $-93.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $63.49M | (m) | $10.50M | $-84.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $56.30M | (m) | $8.63M | $-76.51M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $53.69M | (m) | $7.46M | $-74.26M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $43.58M | (m) | $5.27M | $-63.34M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $41.36M | (m) | $3.49M | $-58.02M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $50.13M | (m) | $8.44M | $1.44M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $43.84M | (m) | $7.06M | $10.96M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $31.05M | (m) | $5.24M | $27.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $47.70M | (m) | $6.89M | $10.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $61.45M | (m) | $8.54M | $-5.40M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $62.54M | (m) | $8.97M | $-5.46M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $70.27M | (m) | $10.67M | $-101.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $72.19M | (m) | $11.52M | $-105.43M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $73.05M | (m) | $13.35M | $-108.14M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $80.22M | (m) | $15.86M | $-117.77M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $83.84M | (m) | $17.32M | $-121.38M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $83.11M | (m) | $18.58M | $-118.84M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $83.70M | (m) | $18.60M | $-118.94M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $89.12M | (m) | $18.23M | $-123.04M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $87.49M | (m) | $17.44M | $-120.52M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $87.24M | (m) | $15.63M | $-120.23M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $84.87M | (m) | $13.41M | $-115.60M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $69.40M | (m) | $10.40M | $-96.94M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $60.80M | (m) | $8.17M | $-84.70M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $54.97M | (m) | $6.80M | $-75.81M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $50.56M | (m) | $5.99M | $-69.05M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $46.75M | (m) | $4.75M | $-63.22M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $41.89M | (m) | $3.54M | $-56.16M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $35.09M | (m) | $2.20M | $-46.24M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $15.19M | (m) | $177.00K | $-18.39M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |